Abstract: A proteoliposome, which is obtained by removing a surfactant from a mixed solution including lipid, membrane proteins and the surfactant, wherein the content of the surfactant in the mixed solution is equal to or more than 1.5 times of the sum of a maximum amount of the surfactant associating with the lipid and a maximum amount of the surfactant associating with the membrane protein. A biochip wherein the above-described proteoliposome is spread on a substrate. A method for producing a proteoliposome by removing a surfactant from a mixed solution including lipid, membrane proteins and the surfactant, wherein the content of the surfactant in the mixed solution is made equal to or more than the sum of a maximum amount of the surfactant associating with the lipid and a maximum amount of the surfactant associating with the membrane protein.

Abstract: A liposome comprising a region of a lipid bilayer membrane with different membrane thicknesses, wherein each lipid bilayer membrane region is composed of a different lipid, and a thick membrane side in the region of the lipid bilayer membrane is formed of lipid having a phase transition temperature higher than that of the lipid forming a thin membrane side in the region of the lipid bilayer membrane. A proteoliposome, wherein the above-described liposome includes membrane proteins. A biochip, wherein the above-described liposome or the above-described proteoliposome is spread on a substrate. The above-described biochip, wherein the substrate includes at least one kind selected from the group consisting of mica, SiO2, SiN, Au and Pt.

Abstract: The present invention provides a modified influenza virus wherein the RNA of the haemagglutinin gene has been modified such that the haemagglutinin signal sequence is not expressed and the virus produces a haemagglutinin protein that lacks a functional signal sequence. The invention further provides composition comprising the modified virus and uses of the modified virus.

Abstract: An electric machine (10; 100) comprises a rotor (14) having permanent magnets (24) and a stator (12) having coils (22) wound on stator bars (16) for interaction with the magnets across an air gap (26a, b) defined between them. The rotor has two stages (14a, b) arranged one at either end of the bars. The bars have a shoe (18a, 8) at each end of each bar that links magnetic flux through the bars with said magnets on each stage. Adjacent shoes facing the same stage of the rotor have a high-reluctance shoe gap (27) between them; adjacent magnets on each stage of the rotor have a high-reluctance magnet gap (25) between them; and the shoe and magnet gaps (25, 27) are angled with respect to each other such that they engage progressively as the rotor rotates. Alternatively, the shoes facing each stage are in a ring of connected shoes such that the magnets experience a continuous reluctance that is at least 90% constant as a function of rotor position.

Abstract: An electric machine comprises a rotor, preferably having permanent magnets, although other field generation means are available, and a stator. The stator has coils wound on stator bars for interaction with the magnetic field of the rotor across an air gap defined between them. The rotor comprises a housing of a chamber containing refrigerant. The rotor housing has heat dissipating fins accessible by the open environment whereby air movement relative to the housing caused at least by rotation of the rotor absorbs heat from the fins. The machine may be an axial flux machine, the coils being wound on bars that are disposed circumferentially spaced around a fixed axle of the machine forming a rotational axis of the rotor. The machine may be a wheel motor for a vehicle, wherein the wheel is mounted directly on the rotor housing.

Abstract: An electrode for use in a electrochemical sensor comprises carbon modified with a chemically sensitive redox-active compound, excluding an electrode based on carbon having derivatized thereron two redox-active species wherein at least one of said species is selected from anthraquinone, phenanthrenequinone and N,N?-diphenyl-p-phenylenediamine (DPPD). The invention further provides a pH sensor comprising: a working electrode comprising carbon modified with a chemically sensitive redox active material; and a counter electrode, wherein the ratio of the surface area of the working electrode to the surface area of the counter electrode is from 1:10 to 10:1. Also provided is a pH sensor comprising: a working electrode comprising carbon modified with a chemically sensitive redox active material, and a counter electrode, wherein the area of the working electrode is from 500 ?m2 to 0.1 m2. The uses of these electrodes and sensors are also described.

Abstract: The invention relates to therapeutic agents for use in the prevention or treatment of Alzheimer's disease. In particular the invention relates to use of inhibitors of cell cycle reentry and progression to the G1/S transition or inhibitors of progression of the cell cycle through the G1/S transition point in the prevention or treatment of Alzheimer's disease.

Abstract: The invention relates to sulphur- and/or selenium-containing compounds that can inhibit the enzyme inositol mono-phosphatase (IMPase), and which can be used in treating conditions that are treatable through inhibition of this enzyme, such as bi-polar disorder, the compounds having a structure of Formula (I), or is a pharmaceutically acceptable salt thereof; Formula (I); in which: E is S or Se and each of phenyl rings A and B is optionally substituted with one or more substituents, in which each substituent is selected independently from: (1) a halogen, which is preferably selected from F, Cl and Br; (2) C1-C4 alkyl, such as C1-C2 alkyl or C1 alkyl, optionally substituted with one or more halogen atoms, each of which is preferably selected from F, Cl and Br; and (3) C1-C4 alkoxy, such as C1-C2 alkoxy or C1 alkoxy; optionally substituted with one or more halogen atoms, each of which is preferably selected from F, Cl and Br.

Abstract: The invention relates to a vaccine for the treatment of disease caused by Neisseria, the vaccine including one or more immunogenic components for Neisseria serogroups, as well as antibodies to the immunogenic components and methods of preventing and treating Neisseria infections. The immunogens are based on elements of the inner core lipopolysaccharide.

Abstract: A method of influencing bronchoconstriction in a mammal comprising applying a stimulation in one or more regions of the brain of the mammal, and an apparatus therefore. The method and apparatus may be used to treat a respiratory disease or sleep apnea.

Abstract: An electric machine comprises a rotor, preferably having permanent magnets, although other field generation means are available, and a stator. The stator has coils wound on stator bars for interaction with the magnetic field of the rotor across an air gap defined between them. The rotor comprises a housing of a chamber containing refrigerant. The rotor housing has heat dissipating fins accessible by the open environment whereby air movement relative to the housing caused at least by rotation of the rotor absorbs heat from the fins. The machine may be an axial flux machine, the coils being wound on bars that are disposed circumferentially spaced around a fixed axle of the machine forming a rotational axis of the rotor. The machine may be a wheel motor for a vehicle, wherein the wheel is mounted directly on the rotor housing.

Abstract: A pharmaceutical comprising a therapeutic protein that hinds to a therapeutic target, the protein being modified with a compound that inhibits binding of the protein to the therapeutic target, the modified protein being effective for reducing an immune response against the protein and for producing a therapeutic effect by binding to the therapeutic target. The therapeutic protein may be an antibody that includes an antibody combining site that binds to the therapeutic target.

Abstract: An electric machine (10;100) comprises a rotor (14a), preferably having permanent magnets (24a,b), although other field generation means are available, and a stator (12). The stator has coils (22) wound on stator bars (16) for interaction with the magnetic field of the rotor across an air gap (26a,b) defined between them. The rotor (14) comprises a housing (54) of a chamber (70) containing refrigerant (82). The rotor housing (54) has heat dissipating fins (96) accessible by the open environment whereby air movement relative to the housing caused at least by rotation of the rotor absorbs heat from the fins. The machine may be an axial flux machine, the coils being wound on bars that are disposed circumferentially spaced around a fixed axle of the machine forming a rotational axis (80) of the rotor. The machine may be a wheel motor for a vehicle, wherein the wheel is mounted directly on the rotor housing (14).

Abstract: An image capture device (2) includes a sensor (4) having an active area comprising a plurality of pixels (6) and a shutter array (8) for controlling the exposure of individual pixels. The pixels are grouped in a plurality of pixel subsets and are arranged to capture a plurality of time-separated lo-res images, which can be viewed sequentially as a movie or data from all the pixels can be used to form a hi-res still image.

Abstract: Arterial spin labelling (ASL) MRI offers a non-invasive means to create blood-borne contrast in vivo for dynamic angiographic imaging. By spatial modulation of the ASL process it is possible to uniquely label individual arteries over a series of measurements, allowing each to be separately identified in the resulting images. This separation requires appropriate analysis for which a general framework has previously been proposed. Here the general framework is modified for fast analysis of non-invasive imaging of blood flow using vessel encoded arterial spin labelling (VE-ASL). This specifically addresses the issues of computational speed of the analysis and the robustness required to deal with real patient data. The modification applies various approaches for estimation of one or more parameters that change the way a vessel, for example an artery, is encoded to provide the fast analysis.

Abstract: Systems and methods are disclosed for quantifying absolute blood volume flow rates by fitting a kinetic model incorporating blood volume, bolus dispersion and signal attenuation to dynamic angiographic data. A self-calibration method is described for both 2D and 3D data sets to convert the relative blood volume parameter into absolute units. The parameter values are then used to simulate the signal arising from a very short bolus, in the absence of signal attenuation, which can be readily encompassed within a vessel mask of interest. The volume flow rate can then be determined by calculating the blood volume within the vessel mask and dividing by the simulated bolus duration. This method is exemplified using non-contrast magnetic resonance imaging data from a flow phantom and the cerebral arteries of healthy volunteers and a patient with Moya-Moya disease acquired using a 2D vessel-encoded pseudo-continuous arterial spin labeling pulse sequence.

Abstract: An image capture device (2) includes a sensor (4) having an active area comprising a plurality of pixels (6) and a shutter array (8) for controlling the exposure of individual pixels. The pixels are grouped in a plurality of pixel subsets and are arranged to capture a plurality of time-separated lo-res images, which can be viewed sequentially as a movie or combined to form a hi-res still image.

Abstract: The present invention relates to immunogenic peptides and their various applications. In particular the invention relates to immunogenic peptides derived from the PASD1 protein and their use in therapeutic, diagnostic and prognostic methods.

Abstract: Systems and methods for analyzing spectra are described. In analyzing the spectra, peaks are identified, and complexes and sub-complexes are assigned to their respective peaks.

Abstract: The invention relates to therapeutic agents for use in the prevention or treatment of Alzheimer's disease. In particular the invention relates to use of inhibitors of cell cycle re-entry and progression to the G1/S transition or inhibitors of progression of the cell cycle through the G1/S transition point in the prevention or treatment of Alzheimer's disease.